Inflammation and metabolic disorders resulting from NLRP3 inflammasome activation via G protein-coupled receptor 35 (GPR35) can be mitigated by kynurenic acid, synthesized from kynurenine by the PLP enzyme kynurenine aminotransferase (KAT) [47] (Table 1). This evidence concerns the gene GPR35 and metabolic disease.